VBI Vaccines (VBIV) Stock Analysis

What VBI Vaccines does

VBI Vaccines Inc. is a biopharmaceutical firm dedicated to the development and commercialization of vaccines, targeting both infectious diseases and immuno-oncology. Among its commercial offerings is Sci-B-Vac, a prophylactic vaccine designed to prevent hepatitis B (HBV). The company is also actively developing VBI-2601 (also identified as BRII-179), an investigational immunotherapeutic aimed at treating chronic hepatitis B infection. A cornerstone of its research and development is the proprietary enveloped virus-like particle (eVLP) platform. This technology facilitates the creation of eVLP vaccines engineered to mimic viral structures, thereby effectively prompting a human immune response. Among the primary candidates leveraging this eVLP platform are VBI-1901, an immunotherapeutic vaccine targeting glioblastoma, which is currently undergoing Phase I/IIa clinical study, and VBI-1501, a prophylactic vaccine candidate against cytomegalovirus, having already completed its Phase I clinical trial. Further enhancing its pipeline, VBI is developing several coronavirus vaccine candidates, including VBI-2902 and VBI-2901. Beyond its direct pipeline, the company also engages in the strategic development of vaccine platforms and products designed for out-licensing to other pharmaceutical and biotechnology entities. VBI maintains significant collaborative and licensing agreements with key partners such as Brii Biosciences Limited and GlaxoSmithKline Biologicals S.A. Furthermore, it collaborates with the National Research Council of Canada to develop a broad-spectrum pan-coronavirus vaccine targeting COVID-19, SARS, and MERS. A partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) aims to advance vaccine candidates specifically against emerging COVID-19 variants. Originally established as SciVac Therapeutics Inc., the company rebranded to VBI Vaccines Inc. in May 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.

Key metrics

ETFs linked to VBIV

Broad-market and Healthcare sector ETFs an investor holding VBI Vaccines is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how VBIV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for VBI Vaccines?

VBI Vaccines trades under the ticker VBIV on NASDAQ.

Which exchange is VBIV listed on?

VBIV is listed on NASDAQ.

What sector does VBI Vaccines operate in?

VBI Vaccines is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze VBIV in a portfolio?

PortView shows VBIV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.